Market Overview

Aegis Capital Reiterates Buy Rating on Galectin Therapeutics After FDA Approval


Aegis Capital published a report Tuesday on Galectin Therapeutics (NASDAQ: GALT) that reiterated its Buy rating and $7.00 price target after the receipt of FDA approval.

In the report, Aegis Capital wrote, "This morning, Galectin announced that the FDA has approved its Investigational New Drug (IND) application for permission to begin first-in-man testing of its lead drug candidate GR-MD-02. A Phase 1 study of the drug is now slated to start patient dosing by May 2013 and is expected to yield data later in the year. Patients with non-alcoholic steatohepatitis (NASH) who exhibit advanced fibrotic disease are slated to be enrolled at up to seven centers in the U.S. The firm's Phase 2 study in NASH, a highly unmet medical need with no currently-approved effective therapy, could begin before the end of 2013 and yield data in early 2015, potentially paving the way for a transformative partnership or potentially an acquisition of the company."

Galectin Therapeutics closed Monday at $3.32 and is currently up 5.42 percent at the time of this writing.

Latest Ratings for GALT

Aug 2020HC Wainwright & Co.MaintainsBuy
Apr 2020B. Riley FBRMaintainsBuy
Mar 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for GALT
View the Latest Analyst Ratings


Related Articles (GALT)

View Comments and Join the Discussion!

Posted-In: Aegis CapitalAnalyst Color Reiteration Analyst Ratings

Latest Ratings

NOMDBTIGInitiates Coverage On30.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at